[go: up one dir, main page]

AR051826A1 - Composiciones inmunogenicas de antigenos polipeptidicos de staphylococcus epidermidis - Google Patents

Composiciones inmunogenicas de antigenos polipeptidicos de staphylococcus epidermidis

Info

Publication number
AR051826A1
AR051826A1 ARP050104384A ARP050104384A AR051826A1 AR 051826 A1 AR051826 A1 AR 051826A1 AR P050104384 A ARP050104384 A AR P050104384A AR P050104384 A ARP050104384 A AR P050104384A AR 051826 A1 AR051826 A1 AR 051826A1
Authority
AR
Argentina
Prior art keywords
staphylococcus epidermidis
immunogenic compositions
refers
polypeptides
polypeptidic
Prior art date
Application number
ARP050104384A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR051826A1 publication Critical patent/AR051826A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente se refiere a composiciones inmunologicas, que comprenden polipéptidos aislados de Staphylococcus epidermidis. La presente se refiere también a polinucleotidos que codifican polipéptidos de Staphylococcus epidermidis y a su uso en composiciones inmunogénicas. Además, la presente se refiere a métodos para inducir una respuesta inmune en mamíferos contra Staphylococcus epidermidis y Staphylococcus aureus usando composiciones inmunogénicas de los polipéptidos y polinucleotidos de Staphylococcus epidermidis. Se refiere también a métodos para detectar Staphylococcus epidermidis en una muestra biologica.
ARP050104384A 2004-10-21 2005-10-20 Composiciones inmunogenicas de antigenos polipeptidicos de staphylococcus epidermidis AR051826A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62078804P 2004-10-21 2004-10-21

Publications (1)

Publication Number Publication Date
AR051826A1 true AR051826A1 (es) 2007-02-14

Family

ID=37595601

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104384A AR051826A1 (es) 2004-10-21 2005-10-20 Composiciones inmunogenicas de antigenos polipeptidicos de staphylococcus epidermidis

Country Status (13)

Country Link
US (3) US8445000B2 (es)
EP (4) EP1802335A2 (es)
JP (2) JP2008517918A (es)
KR (1) KR20070068455A (es)
CN (1) CN101175508A (es)
AR (1) AR051826A1 (es)
AU (1) AU2005333603A1 (es)
BR (1) BRPI0516974A (es)
CA (1) CA2583121A1 (es)
IL (1) IL182546A0 (es)
TW (1) TW200619228A (es)
WO (1) WO2007001423A2 (es)
ZA (1) ZA200703274B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2468803B (en) * 2005-05-19 2011-01-19 Exocyte Ltd Screening methods for bacterial killing
EP2419129A2 (en) * 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus
JP5395264B2 (ja) 2009-06-22 2014-01-22 ワイス・エルエルシー 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）抗原の免疫原性組成物
US20110200995A1 (en) * 2009-09-04 2011-08-18 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the detection, screening, isolation and sequencing of vancomycin resistance genes and vancomycin resistant enterococci
SG10201605500TA (en) 2011-07-06 2016-08-30 Novartis Ag Cationic oil-in-water emulsions
EP3424495A1 (en) 2011-07-06 2019-01-09 GlaxoSmithKline Biologicals S.A. Oil-in-water emulsions that contain nucleic acids
US20150202277A1 (en) * 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
KR20160132109A (ko) * 2014-03-26 2016-11-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 돌연변이 스태필로코쿠스 항원
WO2018072031A1 (en) * 2016-10-21 2018-04-26 Socpra Sciences Et Génies S.E.C. Vaccine constructs and uses thereof against staphylococcus infections
IL284077B1 (en) * 2019-01-30 2025-01-01 Fujifilm Electronic Mat Usa Inc Container and method for making it
KR102627009B1 (ko) * 2021-12-17 2024-01-19 (주)메디톡스 피부 유해 세균에 대한 항세균 활성을 갖는 세균 균주, 및 이를 포함하는 약제학적 조성물

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4837151A (en) 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
DE3751873T2 (de) 1986-04-09 1997-02-13 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
DK0648127T3 (da) 1991-11-22 2003-05-19 Univax Biolog Inc Type I- og type II-overfladeantigener associeret med Staphylococcus epidermidis
JPH07507854A (ja) 1991-12-23 1995-08-31 ツォッヒェ，ミヒャエル 油除去装置を備えたエンジン
PT635132E (pt) 1992-03-19 2001-03-30 Henry M Jackson Found Advanc M Anticorpos opsonicos amplamente reactivos que reagem com antigenios de estafilococos comuns
CA2153593C (en) * 1993-01-26 2010-04-13 David B. Weiner Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US6995008B1 (en) * 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
IL112820A0 (en) * 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2169153T3 (es) * 1994-09-21 2002-07-01 Jackson H M Found Military Med Anticuerpos opsonicos ampliamente reactivos que reaccionan con antigenos estafilococicos comunes.
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
WO1997014800A1 (en) * 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
US6168918B1 (en) 1996-01-31 2001-01-02 American Home Products Corp. Method of detecting foreign DNA integrated in eukaryotic chromosomes
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US7060458B1 (en) * 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
EP1117772B1 (en) * 1998-08-31 2012-10-24 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
DK1117435T3 (da) 1998-09-30 2008-03-17 Wyeth Corp Muteret cholera-holotoxin som adjuvans
US6703492B1 (en) * 1999-11-09 2004-03-09 Smithkline Beecham Corporation Staphylococcus epidermidis nucleic acids and proteins
WO2001034809A2 (en) * 1999-11-09 2001-05-17 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
WO2002074324A1 (en) * 2001-03-15 2002-09-26 The Texas A & M University System Collagen-binding adhesin from staphylococcus epidermidis and method of use
BR0210216A (pt) 2001-06-07 2004-06-08 Wyeth Corp Holotoxina do cólera imunogênica, mutante (ct-crm), composição imunogênica, métodos para aumentar a resposta imune de um hospedeiro vertebrado a um antìgeno, e para produzir uma holotoxina do cólera imunogênica, mutante, sequência ou molécula de ácido nucleico isolado e purificado, célula hospedeira, e, uso de uma holotoxina do cólera mutante
US7285281B2 (en) 2001-06-07 2007-10-23 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
ATE542829T1 (de) * 2001-08-02 2012-02-15 Univ Sheffield Impfstoff
KR101062525B1 (ko) 2002-11-12 2011-09-06 더 브리검 앤드 우먼즈 하스피털, 인크. 포도상구균 감염에 대한 다당류 백신
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
ATE449177T1 (de) * 2003-03-31 2009-12-15 Intercell Ag Staphylococcus epidermidis antigene
WO2006032475A2 (en) * 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Staphylococcal immunogenic compositions
EP2333066B1 (en) 2005-03-25 2015-02-18 National Research Council of Canada Method for isolation of soluble polypeptides

Also Published As

Publication number Publication date
AU2005333603A1 (en) 2007-01-04
EP2213298A2 (en) 2010-08-04
CN101175508A (zh) 2008-05-07
US20150196629A1 (en) 2015-07-16
BRPI0516974A (pt) 2008-09-30
TW200619228A (en) 2006-06-16
ZA200703274B (en) 2008-06-25
KR20070068455A (ko) 2007-06-29
JP2013121981A (ja) 2013-06-20
EP2340848A3 (en) 2011-09-14
WO2007001423A2 (en) 2007-01-04
JP2008517918A (ja) 2008-05-29
EP2298341A2 (en) 2011-03-23
WO2007001423A3 (en) 2007-11-15
EP2213298A3 (en) 2011-07-20
US20130209501A1 (en) 2013-08-15
US20070292450A1 (en) 2007-12-20
US8445000B2 (en) 2013-05-21
IL182546A0 (en) 2008-12-29
EP2340848A2 (en) 2011-07-06
EP1802335A2 (en) 2007-07-04
CA2583121A1 (en) 2007-01-04
EP2298341A3 (en) 2011-07-13

Similar Documents

Publication Publication Date Title
CO6440592A2 (es) Composiciones para inmunizacion contra staphylococcus aureus
SV2008002972A (es) Composiciones, metodos y usos de anticuerpos humanos anti-il-23 ref. cen5117sv
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
CR20160570A (es) Anticuerpos anti-pld1 y su uso para mejorar la función de las celulas t
CY1122911T1 (el) ΑΝΟΣΟΘΕΡΑΠΕΙΑ ΜΕ ΤΗ ΧΡΗΣΗ ΚΥΤΤΑΡΟΥ ΤΟ ΟΠΟΙΟ ΕΧΕΙ ΤΗΝ ΙΚΑΝΟΤΗΤΑ ΣΥΝΕΚΦΡΑΣΗΣ ΑΝΤΙΓΟΝΟΥ ΣΤΟΧΟΥ ΚΑΙ CD1d ΚΑΙ ΕΙΝΑΙ ΔΙΕΓΕΡΜΕΝΟ ΜΕ ΣΥΝΔΕΤΗ CD1d
CR20150088A (es) Anticuerpos anti-notch1 nrr
AR057253A1 (es) Anticuerpos anti-ox40l y metodos que los utilizan
BR0309492A (pt) Uso de pelo menos um álcool ramificado alcoxilado
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
BRPI0621181A8 (pt) Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico
BRPI0708344B8 (pt) vetores adenovirais quiméricos e composição imunogênica
ECSP077888A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
ECSP088831A (es) Anticuerpos anti-tat226 e inmunoconjugados
AR051826A1 (es) Composiciones inmunogenicas de antigenos polipeptidicos de staphylococcus epidermidis
DK2068918T3 (da) Vaccinesammensætning omfattende syntetisk adjuvant
HN2011000357A (es) Composiciones y metodos para anticuerpos que que se dirigen a la proteina de complemento c5
ATE426412T1 (de) Adjuvante influenza-vakzine
WO2007052059A3 (en) Changing th1/th2 balance in split influenza vaccines with adjuvants
BRPI0619795B8 (pt) composição imunogênica, composição adjuvante, e, uso de uma composição imunogênica e um adjuvante
MX2007002787A (es) Adyuvante de glicosilceramida para antigenos de sacarido.
AR063640A1 (es) Anticuerpos agonistas de trkb y usos de los mismos
CL2011000368A1 (es) Aparato para obtener una muestra de estigmas individuales de una barba de estigmas de una planta de maiz que comprende un primer brazo que porta dos hojas separadas, un segundo brazo, una conexion entre los brazos adaptados para permitir la traslacion de las hojas y el eje romo entre si, y sistema de obtencion de un recuento cuantitativo de trozos.
AR059096A1 (es) Anticuerpos anti- efrina -b2 y metodos que usan estos
BRPI0713330A2 (pt) adjuvantes e métodos de uso
CR10280A (es) Anticuerpos de la efgl7 y metodos de uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure